跳至主要内容
临床试验/NCT05830136
NCT05830136招募中不适用

The Application of Sodium Bicarbonate Ringer's Solution on Perioperative Lactic Acid Concentration and Early Recovery Quality in Patients Undergoing Laparoscopic Hepatectomy

The First Affiliated Hospital with Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
lactic values

研究概览

简要总结

Compared the effects of Sodium bicarbonate Ringer's solution and lactate Ringer's solution on the internal environment and hemodynamics of patients during laparoscopic liver resection, to observe the application prospect of sodium bicarbonate Ringer's solution in Laparoscopic hepatectomy.

详细描述

The study was a single-center prospective randomized controlled study. A total of 100 patients undergoing laparoscopic hepatectomy under general anesthesia were randomly divided into 2 groups: Group A, sodium bicarbonate Ringer's solution group(n=50); Group B, Lactate Ringer's solution group (intraoperative crystal fluid dilatation was lactate ringer's injection, n=50); Collect patients' arterial blood gas, blood pressure, heart rate, peripheral vascular resistance, heart rate, blood vessels, the active drug usage, 5% sodium bicarbonate injection usage, inflammation factors, transaminase, creatinine, etc. with the point of preoperative (T0), during liver specimens resected(T1), after liver specimens resected(T2), and the end of surgery (T3). Then statistical analysis and observe the application prospect of sodium bicarbonate Ringer's injection in Laparoscopic hepatectomy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥18 years old,
  • patients who plan to undergoing laparoscopic hepatectomy ;
  • Willing to sign informed consent.

排除标准

  • age <18 years
  • active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
  • history of significant cerebrovascular disease
  • restrictive or obstructive pulmonary disease
  • uncontrolled hypertension
  • renal dysfunction (glomerular filtration rate <60 mL/min),
  • evidence of hepatic metabolic disorder (bilirubin >35 mmol/L)
  • presence of active infection

研究组 & 干预措施

Group A

Experimental

Sodium bicarbonate Ringer's solution group

干预措施: sodium bicarbonate Ringer's solution (Drug)

Group B

Active Comparator

Lactate Ringer's solution group

干预措施: sodium bicarbonate Ringer's solution (Drug)

结局指标

主要结局

lactic values

时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

to compare the conditions of acid-base balance and internal environment between the two groups

次要结局

  • Concentration of BUN(day 1 and day 3 after surgery.)
  • Amount of norepinephrine(From the start of operation until the end of operation (during the operation).)
  • Amount of phenylephrine(From the start of operation until the end of operation (during the operation).)
  • Value of pH(From the start of operation until the end of operation (during the operation).)
  • Value of SVR(From the start of operation until the end of operation (during the operation).)
  • Amount of sodium bicarbonate injection (ml)(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.)
  • Value of HR(From the start of operation until the end of operation (during the operation).)
  • Amount of milrinone(From the start of operation until the end of operation (during the operation).)
  • time of stay in PACU(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.)
  • extubation time(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.)
  • Value of ALT(day 1 and day 3 after surgery.)
  • Amount of blood transfusion(intraoperative)
  • Amount of furosemide(From the start of operation until the end of operation (during the operation).)
  • Concentration of HCO3-(From the start of operation until the end of operation (during the operation).)
  • Value of BE(From the start of operation until the end of operation (during the operation).)
  • Amount of nitroglycerin(From the start of operation until the end of operation (during the operation).)
  • Concentration of Cr(day 1 and day 3 after surgery.)
  • Concentration of Glucose(From the start of operation until the end of operation (during the operation).)
  • Value of MAP(From the start of operation until the end of operation (during the operation).)
  • Concentration of CI(From the start of operation until the end of operation (during the operation).)
  • Value of SVV(From the start of operation until the end of operation (during the operation).)
  • Value of PPV(From the start of operation until the end of operation (during the operation).)
  • Amount of ephedrine(From the start of operation until the end of operation (during the operation).)
  • time of palinesthesia from general anesthsia(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.)
  • Value of AST(day 1 and day 3 after surgery.)
  • Amount of blood loss(intraoperative)
  • urinary output(intraoperative)
  • 15-item quality of recovery scale scores (QoR-15)(day 1 and day 3 after surgery.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shijiang Liu, MD

Clinical Professor

The First Affiliated Hospital with Nanjing Medical University

研究点 (1)

Loading locations...

相似试验